01:37 AM EDT, 10/07/2026 (MT Newswires) -- Abionyx Pharma (ABNX.PA) established a manufacturing partnership with Italian contract development and manufacturing organization Olon to advance the development and commercialization of CER-001 as a treatment for sepsis. The Paris-listed biopharmaceutical company said Wednesday that the partnership will initially focus on two validation batches of CER-001. Subject to regulatory approval, the deal will also satisfy the industrial requirements for the future commercialization of the drug.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.